company background image
IBO logo

Universal Ibogaine TSXV:IBO Stock Report

Last Price

CA$0.01

Market Cap

CA$3.1m

7D

-33.3%

1Y

100.0%

Updated

22 Dec, 2024

Data

Company Financials

My Notes

Capture your thoughts, links and company narrative

Universal Ibogaine Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Universal Ibogaine
Historical stock prices
Current Share PriceCA$0.01
52 Week HighCA$0.03
52 Week LowCA$0.005
Beta5.34
1 Month Change-33.33%
3 Month Change-33.33%
1 Year Change100.00%
3 Year Change-91.67%
5 Year Changen/a
Change since IPO-94.44%

Recent News & Updates

Recent updates

Shareholder Returns

IBOCA HealthcareCA Market
7D-33.3%-0.3%-2.6%
1Y100.0%33.6%15.2%

Return vs Industry: IBO exceeded the Canadian Healthcare industry which returned 33.7% over the past year.

Return vs Market: IBO exceeded the Canadian Market which returned 15.2% over the past year.

Price Volatility

Is IBO's price volatile compared to industry and market?
IBO volatility
IBO Average Weekly Movement70.6%
Healthcare Industry Average Movement4.2%
Market Average Movement8.2%
10% most volatile stocks in CA Market17.4%
10% least volatile stocks in CA Market2.9%

Stable Share Price: IBO's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: IBO's weekly volatility (71%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aNick Karosuniversalibogaine.com

Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. It undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. The company is headquartered in Calgary, Canada.

Universal Ibogaine Inc. Fundamentals Summary

How do Universal Ibogaine's earnings and revenue compare to its market cap?
IBO fundamental statistics
Market capCA$3.09m
Earnings (TTM)-CA$1.56m
Revenue (TTM)CA$2.33m

1.3x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IBO income statement (TTM)
RevenueCA$2.33m
Cost of RevenueCA$1.67m
Gross ProfitCA$659.80k
Other ExpensesCA$2.22m
Earnings-CA$1.56m

Last Reported Earnings

Apr 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0051
Gross Margin28.28%
Net Profit Margin-66.93%
Debt/Equity Ratio171.8%

How did IBO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 05:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/04/30
Annual Earnings2023/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Universal Ibogaine Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution